Aastrom Biosciences (US) gets investigational device exemption (IDE) for stem cell production trial:
This article was originally published in Clinica
Executive Summary
Aastrom Biosciences (US) says it has FDA permission to begin clinical trials of its cell production system (CPS) for cancer patients. The first phase of the trials will involve the treatment of ten breast cancer patients at the MD Anderson Cancer Center, Houston, Tx. Aastrom says that CPS, which produces human stem cells from a 15 ml bone marrow sample, is a much less cumbersome method than those currently used to produce stem cells outside the body.